FMI
JAZZ icon

F/M Investments’s Jazz Pharmaceuticals JAZZ Stock Holding History

F/M Investments’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,580
Closed -$2M – 66
2022
Q4 		$2M Sell
12,580
-911
-7% -$134K 2.43% 14
2022
Q3 		$1.8M Buy
+13,491
New +$2.05M 2.91% 12

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

F/M Investments's JAZZ Position: Q1 2023 in Review

F/M Investments sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2023, closing a stake of 12,580 shares — an estimated $2M sold.

F/M Investments first reported a position in JAZZ in Q3 2022 and held it in 2 quarters. The position peaked at $2M in Q4 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

  • F/M Investments reported no remaining Jazz Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • F/M Investments sold 12,580 Jazz Pharmaceuticals shares in Q1 2023, an estimated $2M.
  • F/M Investments first reported a position in Jazz Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • F/M Investments's Jazz Pharmaceuticals position peaked at $2M in Q4 2022.
  • 471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on F/M Investments's 13F filing for Q1 2023, filed 1 May 2023.